Kamal Jarrah

Title: Kamal Jarrah: Innovator in Pharmaceutical Chemistry

Introduction

Kamal Jarrah is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of stable polymorphs and methods for drug preparation. With a total of three patents to his name, Jarrah's work is essential for advancing treatments for various medical conditions.

Latest Patents

One of Kamal Jarrah's latest patents is focused on a stable polymorph of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-anime with L-tartaric acid. This stable polymorph, known as Form Z1, is particularly suitable for the active pharmaceutical ingredient intended for the treatment of type 2 diabetes. Another significant patent involves a method for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride, commonly known as duloxetine. This method includes reacting duloxetine base with concentrated hydrochloric acid in ethylmethylketone and crystallizing the hydrochloride salt.

Career Highlights

Kamal Jarrah is currently employed at Zentiva, a prominent pharmaceutical company. His work at Zentiva has allowed him to focus on innovative drug formulations and methods that enhance the efficacy and stability of pharmaceutical products. His contributions are vital in ensuring that patients receive effective treatments.

Collaborations

Throughout his career, Kamal Jarrah has collaborated with notable colleagues such as Ludek Ridvan and Josef Cinibulk. These collaborations have fostered a productive environment for innovation and have led to advancements in pharmaceutical research.

Conclusion

Kamal Jarrah's work in pharmaceutical chemistry exemplifies the importance of innovation in developing effective medical treatments. His patents and collaborations highlight his commitment to improving healthcare through scientific advancements.